Divestment of Viela shareholding completed
AstraZeneca has completed the divestment of its 26.7% ownership in Viela Bio, Inc. (Viela), as part of the proposed acquisition of Viela by Horizon Therapeutics plc. This follows the agreement to divest the shareholding on 1 February 2021 . Financial considerations AstraZeneca has received cash proceeds and profit of c.$775m. This will be accounted for in other operating income in the Company’s financial statements. The divestment does not impact the